Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Author:

Salzer Wanda L.1,Asselin Barbara2,Supko Jeffrey G.3,Devidas Meenakshi4,Kaiser Nicole A.5,Plourde Paul6,Winick Naomi J.7,Reaman Gregory H.8,Raetz Elizabeth9,Carroll William L.10,Hunger Stephen P.511

Affiliation:

1. US Army Medical Research and Materiel Command, Fort Detrick, MD;

2. Department of Pediatrics, University of Rochester School of Medicine, Golisano Children’s Hospital at University of Rochester Medical Center, Rochester, NY;

3. Massachusetts General Hospital, Harvard Medical School, Boston, MA;

4. Department of Biostatistics, College of Medicine, College of Public Health & Health Professions, University of Florida, Gainesville, FL;

5. Children’s Hospital Colorado, Aurora, CO;

6. EUSA Pharma, Langhorne, PA;

7. Division of Pediatric Hematology/Oncology, University of Texas Southwestern School of Medicine, Dallas, TX;

8. Department of Hematology-Oncology, Children’s National Medical Center, Washington, DC;

9. New York University Langone Medical Center, New York, NY;

10. New York University Cancer Institute, New York, NY; and

11. Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO

Abstract

Key Points Erwinia asparaginase was granted FDA approval in November 2011 for use in patients with allergic reactions to E coli-derived asparaginase. Erwinia asparaginase 25 000-IU/m2 for 6 intramuscular doses M/W/F can be substituted for a single dose of pegaspargase.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference50 articles.

1. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.;Dolowy;Cancer,1966

2. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.;Appel;Leukemia,2008

3. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies.;Capizzi;Ann Intern Med,1971

4. L-asparaginase in the treatment of neoplastic diseases in children.;Jaffe;Cancer Res,1971

5. L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.;Nesbit;Cancer Treat Rep,1981

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3